PREGABALIN Capsule

País: Canadá

Idioma: francés

Fuente: Health Canada

Ingredientes activos:

Prégabaline

Disponible desde:

SIVEM PHARMACEUTICALS ULC

Código ATC:

N02BF02

Designación común internacional (DCI):

PREGABALIN

Dosis:

225MG

formulario farmacéutico:

Capsule

Composición:

Prégabaline 225MG

Vía de administración:

Orale

Unidades en paquete:

100

tipo de receta:

Prescription

Área terapéutica:

MISCELLANEOUS ANTICONVULSANTS

Resumen del producto:

Numéro de groupe d'ingrédients actifs (GIA) :0151121007; AHFS:

Estado de Autorización:

APPROUVÉ

Fecha de autorización:

2021-04-08

Ficha técnica

0212*53+,('(352'8,7
3U
35(* % /,1
DSVXOHV GHSUpJDEDOLQH
PJ
PJ
PJ
PJ
PJ
PJ
QDOJpVLTXH
'DWHGHUpYLVLRQ
DYULO
6LYHP3URGXLWV3KDUPDFHXWLTXHV 8/
UXH'REULQ
6DLQW/DXUHQW 4XpEHF
+5 3
ZZZVLYHP FD
1XPpUR GHFRQWUOH
^
Sivem
0RQR UDS L GSURGL35( ,1
3D
G
7DEOH GHVPD LqUHV
357,( ,
5(16(,*1(0(1763285/(352)(66,211(/'( /
6
17e
5(16(,*1(0(1766200 ,5(6 685 /( 352'8,7
,1',
7,216(787,/,6
7,21/,1,48(
2175( ,1',7,216
0,6(6(1*5'((7 35e 87,216
())(76 ,1'e6,5%/(6
,17(5
7,2160e',
0(17(86(6
3262/2*,((7'0,1,675 7,21
685'26*(
02'('
7,21(7 3+502/2*,(/,1,48(
(175(326 *( (767%,/,7e
)250(6 3262/2*,48(620326,7,21(7
21',7,211(0(17
357,( ,,5(16(,*1(0(1766 ,(17,),48(6
5(16(,*1(0(1763+ 50
(87,48(6
(66,6/,1,48(6
3+50
2/2*,( 'e7 ,//e(
72;,
2/2*,(
5e)e5(1(6
357,( ,,,
5(16(,*1(0(1763285/(
216200 7(85
0RQR UDS L GSURGL35( ,1
3D
G
3U
35(*% /,1
DSVXOHV GHSUpJDEDOLQH
3 57,( ,
5(16(,*1(0(176 3285/(352)(66,211(/'( /
6
17e
5(16(,*1(0(1766200,5(6685 /(352'8,7
9RLH
GDGPLQLV UDLRQ
)RUPH SRVRORJLTXH
FRQFHQUDLRQ
7RXVOHV LQJUpGLHQ V QRQPpGLFDPHQ HX
2UDOH
DSVXOHVj
PJ
PJ
PJ
PJ
PJHW
PJ
PLGRQ SUpJpOLILp JRPPH ODTXH JpODWLQH
K GUR[GH G DPPRQLXP R[GH GHIHUQRLU
SURS OqQHJO
FRO
WDOFGLR[GHGHWLWDQLXP
/HV WHQHXUVGH
HW
PJ FRQWLHQQHQW
DXVVL GH OR[GHGHIHUURXJH
,1',7,216 (7 87,/,67,21
/,1,48(
35(*%/,1 SUpJDEDOLQH HVWLQGLTXp SRXUOHWUDLWHPHQW
GHODGRXOHXUQHXURSDWKLTXH
DVVRFLpH
•
j OD QHXURSDWKLHGLDEpWLTXH SpULSKpULTXH HW
•
DX[QpYUDOJLHV SRVW]RVWpULHQQHV
35(*%/,1 HVWLQGLTXp SRXUOHWUDLWHPHQW GH ODGRXOHXU
QHXURSDWKLTXHFRQVpFXWLYHj
XQH OpVLRQGH ODPRHOOHpSLQLqUH
35(*%/,1 HVWLQGLTXp SRXUOHWUDLWHPHQW GH ODGRXOHXUDVVRFLpHjODILEURP
DOJLH
/HIILFDFLWp GH35(*% /,1 GDQV OH WUDLWHPHQWGHOD GRXOHXUDVVRFLpHj OD
ILEURPDOJLH
SRXU XQHSpULRGHDOODQWMXVTX j VL[ PRLVDpWpGpPRQWUpHGDQVOH FDGUHGXQ
HVVDL
FRPSDUDWLIDYHFSODFHER PHQpDXSUqVGHSDWLHQWVTXLDYDLHQWGpMjUpSRQGX
DXWUDLWHPHQW
SDU SUpJDEDOLQH ORUVG XQH pWXGHRXYHUWHGHVL[ VHPDLQHV
3HUVRQQHV kJpHV
DQV
/DFODLUDQFHUpQDOHGHOD SUpJDEDOLQHDGPLQLVWUpHSDUYRLH
RUDOHWHQGDLW jGLPLQXHU DYHFOkJHHWWHGLPLQXWLRQ FDGUHDYHF
ODUpGXFWLRQHOOHDXVVL OLpH
jOkJHGHODFODLUDQFHGHODFUpDWLQ